Precision Immunotherapeutics Revenue

About Precision Immunotherapeutics

T-cell activating anti-CD3 antibodies are remarkable antibodies - capable of killing a very wide range of cancers. However, their long-standing problem is that they can be too effective – causing major off-target effects. Interesting approaches to control their target specificity have been developed, including a wide range of bispecific antibodies, but there is still a very real need of employing them at high doses determined not critically only by the level of side effects but by efficacy such that tumours can be hit quickly and very hard. The approach that Precision Immunotherapeutics takes is to make the anti-CD3 antibodies, both in their native and bispecific states, light dependent such that their activities can only be expressed when illuminated at the required site. Bringing this extra level of target-specificity to bear is aimed at opening the door to a multitude of different applications in which high doses of these excellent antibodies can be delivered safely in their ‘cloaked’ form ready for activation to achieve rapid remission, before uncontrollable mutations occur in tumours.

View contact profiles from Precision Immunotherapeutics